Mechanisms of resistance of yeast to antimicotic drugs;Mechanizmy oporności drożdży na stosowane leki przeciwgrzybicze

Mikologia Lekarska

Volumn 15, Issue 1, 2008, Pages 49-53

  Ciok Pater, Emilia ^a,b   Białucha, Agata ^a   Szabelska, Małgorzata ^a   Gospodarek, Eugenia ^a  

^a Katedra i Zak ad Mikrobiologii Collegium Medicum w Bydgoszczy UMK w Toruniu   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Antimicotic drugs; Fungi; Mechanisms of resistance

Indexed keywords

ALLYLAMINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; DRUG METABOLIZING ENZYME; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; CELL MEMBRANE; DRUG MECHANISM; DRUG TARGETING; FUNGAL CELL; NONHUMAN; PHARMACOEPIDEMIOLOGY; REVIEW;

FUNGI;

EID: 42549171981     PISSN: 1232986X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Andersen J.B.: Evolution of antifungal drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol., 2005, 3, 547-556.
2. Martins M.D., Rex J.H.: Resistance to antifungal agents in the critical care setting: problems and perspectives. New Horiz., 1996, 4, 338-344.
3. Zielińska E.: Kontrowersje dotycza̧ce optymalnej profilaktyki i leczenia zakażeń grzybami w stanach obniżonej odporności. Przegl. Epidemiol., 2003, 57, 299-307.
4. Dzierżanowska D.: Wybrane zagadnienia mikrobiologii lekarskiej. Postȩpy w leczeniu inwazyjnych zakażeń grzybiczych. Media Press, 2004, 12, 111-120.
5. Iwata K.: Drug resistance in human pathogenic fungi. Eur. J. Epidemiol., 1992, 8, 407-421.
6. Łukaszuk C., Krajewska-Kułak E., Niczyporuk W., Wojtukiewicz M., Krawczuk-Rybak M.: Wrażliwość na chemioterapeutyki przeciwgrzybicze szczepów grzybów drożdżopodobnych izolowanych od pacjentów z choroba̧ nowotworowa̧. Onkol. Pol., 1999, 4, 1-5.
7. Tyczkowska-Sieroń E., Kurnatowski P.: Analíza zależności pomiȩdzy aktywnościa̧ enzymatyczna̧ a opornościa̧ na flukonazol szczepów grzybów z rodzaju Candida. Mikol. Pol., 2006, 13, 99-103.
8. Ghannoum M.A., Rice L.B.: Antifungal agents: mode of action, mechanisms of resistance and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev., 1999, 4, 501-517.
9. Georgopapadakou N.H., Walsh T.J.: Human mycoses: drugs and targets for emerging pathogens. Science, 1994, 264, 371-373.
10. Georgopapadakou N.H., Walsh T.J.: Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother., 1996, 40, 279-291.
11. Hector R.F.: Compounds active against cell walls of medically important fungi. Clin. Microbiol. Rev., 1993, 6, 1-21.
12. Hitchcock C.K., Dickinson S.B., Brown E.G., Adams D.J.: Interaction of azole antifungal antibiotics with cytochrome P450-dependent 14 a-sterol demethylase purified from Candida albicans. J. Biochem., 1999, 266, 475-480.
13. Ryder N., Favre B.: Antifungal activity and mechanism of action of terbinafine. Rev. Contemp. Pharmacother., 1997, 8, 275-287.
14. Sheehan D.J., Hitchcock C.A., Sibley C.M.: Current and emerging azole antifungal agents. Clin. Microbiol. Rev., 1999, 12, 40-79.
15. Geber A., Hitchcock C.A., Swartz J.E., Pullen F.S., Marsden K.E., Kwon-Chung K.J., Bennett J.: Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother., 1995, 39, 2708-2717.
16. Sanati H., Belanger P., Fratti R., Ghannoum M.: A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob. Agents Chemother., 1997, 41, 2492-2496.
17. Ghannoum M., Spellberg B.J., Ibrahim A., Ritchie J.A., Currie B., Spitzer E., Edwards J.E., Casadevall A.: Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob. Agents Chemother., 1994, 38, 2029-2033.
18. Vanden Bossche H., Marichal H.P., Le Jeune L., Coene M., Gorrens J., Cools W.: Effects of itraconazole on cytochrome P-450-dependent 14 a-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob. Agents Chemother., 1993, 37, 2101-2105.
19. Hitchcock C.A., Barrett-Bee K.A., Russell N.J.: The lipid composition and permeability to azole of an azole - and polyene-resistant mutant of Candida albicans. J. Med. Vet. Mycol., 1987, 25, 29-37.
20. Orozco A., Higginbotham L., Hitchcock C., Parkinson T., Falconer D., Ibrahim A., Ghannoum M., Filler S.G.: Mechanism of fluconazole resistance in Candida krusei. Antimicrob. Agents Chemother., 1998, 42, 2645-2649.
21. Vanden Bossche H., Marichal H.P., Odds F., Le Jeune L., Coene M.C.: Characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother., 1992, 36, 2602-2610.
22. Gottesman M.M., Pastan I.: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 1993, 62, 385-427.
23. Prasad R., de Wergifosse P., Goffeau A., Balzi E.: Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet., 1995, 27, 320-329.
24. Walsh T.J., Kasai M., Francesconi A., Landsman D., Chanock S.J.: New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: implications for antifungal azole resistance. J. Med. Vet. Mycol., 1996, 35, 133-137.
25. White T.C.: Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother., 1997, 41, 1482-1487.
26. Hitchcock C., Whittle P.T.: Chemistry and mode of action of fluconazole. [w:] J.W. Rippon, R.A. Fromtling: Cutaneous antifungal agents: selected compounds in clinical practice and development. Marcel Dekker, Inc., New York, 1993, 183-197.
27. Fryberg M.: Sterol biosynthesis in antibiotic-resistant yeast: nystatin. Arch. Biochem. Biophys., 1974, 160, 83-89.
28. Ather M.A., Winner H.I.: Development of resistance by Candida species to polyene antibiotics in vitro. J. Med. Microbiol., 1971, 4, 505-517.
29. Hamilton-Miller J.M.T.: Chemistry and biology of the polyene macrolide antibiotics. Bacteriol. Rev., 1973, 37, 166-196.
30. Mbongo N., Loiseau P.M., Billion M.A., Robert-Gero M.: Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 1998, 42, 352-357.
31. Sanglard D., Ischer F., Monod M., Bille J.: Susceptibility of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother., 1996, 40, 2300-2305.
32. Kurtz M.B.: New antifungal drug targets: a vision for the future. ASM News., 1997, 64, 31-39.
33. Kurtz M.B., Douglas C.M.: Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol., 1997, 35, 79-86.
34. Jund R., Lacroute F.: Genetic and physiological aspects of resistance to 5-fluoropyrimidines in Saccharomyces cerevisiae. J. Bacteriol., 1970, 102, 607-615.